Bayer takes BNP (B-type natriuretic peptide) assay to smaller laboratories:
This article was originally published in Clinica
Bayer Diagnostics is expanding the availability of its BNP assay, used to help diagnose heart failure, to small-volume laboratories. After launching the test in the US in 2003 for use on the ADVIA Centaur system used in larger labs, the company is now offering it for use on the ACS:180 immunoassay system in the US and other markets. BNP (B-type natriuretic peptide) testing is gathering pace following findings that elevated levels in the blood can indicate heart failure. Similar tests are already offered in the US by Roche Diagnostics and Biosite, and several others are being developed by other companies.